So, as usual, EHA and ASCO are one after the other one, and the myeloma abstracts are becoming very dominant in both of the meetings. And this year, I’m one of the authors of the MonumenTAL-3, which is going to be in the plenary session, and we are very happy to see the results, very positive results, and many people have seen the abstract already. And so it’s a new step for, similar to the MajesTEC-3, where the combination of teclistamab with daratumumab produced a fantastic outcome...
So, as usual, EHA and ASCO are one after the other one, and the myeloma abstracts are becoming very dominant in both of the meetings. And this year, I’m one of the authors of the MonumenTAL-3, which is going to be in the plenary session, and we are very happy to see the results, very positive results, and many people have seen the abstract already. And so it’s a new step for, similar to the MajesTEC-3, where the combination of teclistamab with daratumumab produced a fantastic outcome. Now the same success is now being replicated with talquetamab-daratumumab combination with or without pomalidomide. So this is another triplet which is applicable for patients who are relapsing beyond first relapse. So this is one of the presentations that I’m looking forward to.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.